Sign In
Buy HAE
$65.88
-0.490 (-0.738%)
At Close: Jun 03, 2026
CAMBRIDGE, Mass., June 15, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
BioCryst Highlights Real-world Data Showing ORLADEYO® (berotralstat) Consistently Reduces HAE Attacks Across All Ages
07:00am, Friday, 30'th May 2025
New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supports berotralstat use at all stages of life New data shared at the 14th C1-inhibitor Deficiency & Angioedema Workshop supp
Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference
06:00am, Friday, 30'th May 2025
BOSTON , May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th An
RESEARCH TRIANGLE PARK, N.C., May 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new real-world evidence on the use of oral, once-daily ORLADEYO® (berotra
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
09:40am, Monday, 12'th May 2025
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
Pharvaris to Host a Virtual R&D Call “Deucrictibant: Beyond HAE Type 1/2” on June 4
06:50am, Monday, 12'th May 2025
Expansion of potential treatment applications of deucrictibant in people living with bradykinin-mediated angioedema Expansion of potential treatment applications of deucrictibant in people living with
Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
01:05pm, Saturday, 10'th May 2025
Haemonetics Corporation (NYSE:HAE ) Q4 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Olga Guyette – Vice President-Investor Relations & Treasury Chris Simon – Chief Exe
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
09:30pm, Friday, 09'th May 2025
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estim
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
10:20am, Thursday, 08'th May 2025
Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
06:00am, Thursday, 08'th May 2025
Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
10:21am, Wednesday, 07'th May 2025
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
11:05am, Thursday, 01'st May 2025
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
08:30am, Thursday, 01'st May 2025
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced results from a new survey showing that 91% of surveyed adults living with hereditary angioedema (HAE) were
KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan
06:30am, Tuesday, 08'th Apr 2025
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that its wholly-owned subsidiary, KalVista Pharmaceuticals, Ltd., has licensed com
